2020-11-25 11:55:35 DBOEY Deutsche Boerse
11/25/20 11/2511:55 11/25/2011:55 | Deutsche Boerse price target raised to EUR 165 from EUR 160 at UBSUBS analyst Michael Werner raised the firm's price target on Deutsche Boerse to EUR 165 from EUR 160 and keeps a Buy rating on the shares. | |
---|---|---|
|
Upgrade
|
Bank of Montreal upgraded to Outperform from Sector Perform at National Bank »
21:30 03/07/21 03/0721:30 03/07/2121:30
BMO
Bank of Montreal
National Bank analyst… National Bank analyst Gabriel Dechaine upgraded Bank of Montreal to Outperform from Sector Perform with a price target of C$121, up from C$113. Signs of a lending recovery will be positive for investor sentiment and drive potential revisions to "relatively low" earnings growth anticipated next year, Dechaine tells investors in a research note. ShowHide Related Items >><<
|
Upgrade
|
Surge Energy upgraded to Outperform from Sector Perform at National Bank »
21:28 03/07/21 03/0721:28 03/07/2121:28
ZPTAF
Surge Energy
National Bank analyst… National Bank analyst Endri Leno upgraded Surge Energy to Outperform from Sector Perform with a price target of C$0.90, up from C$0.75. The sale of the Eyehill assets "restores the company and its value opportunity," Leno tells investors in a research note. ShowHide Related Items >><<
|
Recommendations
|
Aslan Pharmaceuticals price target lowered to $9 from $10 at Piper Sandler »
20:37 03/07/21 03/0720:37 03/07/2120:37
ASLN
Aslan Pharmaceuticals
Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Aslan Pharmaceuticals to $9 from $10 and reiterates an Overweight rating on the shares. The analyst trimmed the target to account for dilution from the 15M share offering. ShowHide Related Items >><<
|
Hot Stocks
|
Fly Intel: Top five weekend stock stories »
20:01 03/07/21 03/0720:01 03/07/2120:01
GE
General Electric
AerCap
Microsoft
NewHold Investment Corp.
Lowe's
Disney
Mytheresa
Vertex Pharmaceuticals
Broadcom
Cisco
Qualcomm
Texas Instruments
Catch up on the… Catch up on the weekend's top five stories with this list compiled by The Fly: 1. General Electric (GE) is nearing a $30B-plus deal to combine its aircraft-leasing business with Ireland's AerCap (AER), The Wall Street Journal's Cara Lombardo and Emily Glazer reported, citing people familiar with the matter. Though details of how the deal would be structured couldn't be learned, it is expected to have a valuation of more than $30B, some of the people said. An announcement is expected Monday, assuming the talks don't fall apart, the authors added. 2. Evolv Technology is combining with a special-purpose acquisition company to go public in a deal that values the crowd-safety company at about $1.7B, The Wall Street Journal's Amrith Ramkumar reported. Backed by investors including Microsoft (MSFT) co-founder Bill Gates and former Florida Gov. Jeb Bush, Evolv is merging with the SPAC NewHold Investment Corp. (NHIC), the author noted. 3. Lowe's (LOW) was a lockdown winner and investors are having second thoughts about its stock now that reopening looms, but Lowe's is far more than just a COVID-19 play, Teresa Rivas wrote in this week's edition of Barron's. Concerns are probably overblown and with COVID receding, Lowe's is set to become a more profitable company, while housing might be more resilient than it's given credit for, the author contended. 4. Disney's (DIS) "Raya and the Last Dragon" easily won the weekend box office, the biggest since pandemic shut down theaters as New York City was finally allowed to reopen at 25% capacity. The movie sports an A CinemaScore and took in an estimated $8.6M in its North American debut. Overseas, "Raya and the Last Dragon" earned $17.6M from 32 markets for a global total of $26.2M. 5. Mytheresa (MYTE), Vertex Pharmaceuticals (VRTX), Broadcom (AVGO), Cisco (CSCO), Qualcomm (QCOM) and Texas Instruments (TXN) saw positive mentions in this week's edition of Barron's. ShowHide Related Items >><<
|
Periodicals
|
Evolv going public in $1.7B SPAC merger, WSJ reports »
19:56 03/07/21 03/0719:56 03/07/2119:56
MSFT
Microsoft
NewHold Investment Corp.
Evolv Technology is… Evolv Technology is combining with a special-purpose acquisition company to go public in a deal that values the crowd-safety company at about $1.7B, The Wall Street Journal's Amrith Ramkumar reports. Backed by investors including Microsoft (MSFT) co-founder Bill Gates and former Florida Gov. Jeb Bush, Evolv is merging with the SPAC NewHold Investment Corp. (NHIC), the author notes. Reference Link ShowHide Related Items >><<
|
Periodicals
|
GE nears deal to combine aircraft-leasing unit with AerCap, WSJ reports »
19:52 03/07/21 03/0719:52 03/07/2119:52
GE
General Electric
AerCap
General Electric (GE) is… General Electric (GE) is nearing a $30B-plus deal to combine its aircraft-leasing business with Ireland's AerCap (AER), The Wall Street Journal's Cara Lombardo and Emily Glazer report, citing people familiar with the matter. Though details of how the deal would be structured couldn't be learned, it is expected to have a valuation of more than $30B, some of the people said. An announcement is expected Monday, assuming the talks don't fall apart, the authors add. Reference Link ShowHide Related Items >><<
|
Upgrade
|
Franco-Nevada upgraded to Outperform from Market Perform at BMO Capital »
19:49 03/07/21 03/0719:49 03/07/2119:49
FNV
Franco-Nevada
BMO Capital analyst… BMO Capital analyst Jackie Przybylowski upgraded Franco-Nevada to Outperform from Market Perform with a C$97 price target. The analyst cites an optimistic outlook for royalty and streaming companies in general and for Franco-Nevada in particular. ShowHide Related Items >><<
|
Upgrade
|
Wheaton Precious Metals upgraded to Outperform from Market Perform at BMO Capital »
19:47 03/07/21 03/0719:47 03/07/2119:47
WPM
Wheaton Precious Metals
BMO Capital analyst… BMO Capital analyst Jackie Przybylowski upgraded Wheaton Precious Metals to Outperform from Market Perform with a $57 price target. The analyst cites an optimistic outlook for royalty and streaming companies in general and for Wheaton Precious Metals in particular. ShowHide Related Items >><<
|
On The Fly
|
Box Office Battle: 'Raya' wins biggest weekend since shutdown »
18:15 03/07/21 03/0718:15 03/07/2118:15
T
AT&T
Comcast
Comcast
Sony
Lionsgate
Lionsgate
Disney
ViacomCBS
ViacomCBS
Disney’s (DIS) "Raya… ShowHide Related Items >><<
|
Periodicals
|
Biden sees $1,400 payments starting to go out this month, Reuters says »
17:50 03/07/21 03/0717:50 03/07/2117:50
SPY
SPDR S&P 500 ETF Trust
S&P 500
President Joe Biden said… President Joe Biden said that Senate passage of his $1.9T coronavirus aid bill means that $1,400 payments to most Americans will start to go out this month and the bill's provisions will speed up manufacturing and distribution of vaccines, according to Reuters. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Austria suspends AstraZeneca COVID vaccine batch after death, Reuters says »
17:38 03/07/21 03/0717:38 03/07/2117:38
AZN
AstraZeneca
Austrian authorities have… Austrian authorities have suspended inoculations with a batch of AstraZeneca's COVID-19 vaccine as a precaution while investigating the death of one person and the illness of another after the shots, Reuters' Michael Shields and Ludwig Burger report, citing a health agency. Reference Link ShowHide Related Items >><<
|
Periodicals
|
White House urges action despite Microsoft patch amid active threat, Reuters says »
17:32 03/07/21 03/0717:32 03/07/2117:32
MSFT
Microsoft
The White House urged… The White House urged computer network operators to take further steps to gauge whether their systems were targeted amid a hack of Microsoft's Outlook email program, saying a recent software patch still left serious vulnerabilities, Reuters' Jeff Mason reports. "This is an active threat still developing and we urge network operators to take it very seriously," a White House official said, adding that top U.S. security officials were working to decide what next steps to take following the breach. Reference Link ShowHide Related Items >><<
|
Hot Stocks
|
Moderna to provide 13M doses of COVID vaccine to Philippines »
16:21 03/07/21 03/0716:21 03/07/2116:21
MRNA
Moderna
Moderna has announced a… Moderna has announced a supply agreement with the Government of The Philippines for 13M doses of the COVID-19 Vaccine Moderna. Under the terms of this agreement, deliveries would begin in mid-2021. The COVID-19 Vaccine Moderna is not currently approved for use in the Philippines, and the company will work with regulators to pursue necessary approvals prior to distribution. A separate agreement with the Philippine Government and private sector for the supply of an additional 7M doses is also anticipated. ShowHide Related Items >><<
|
Hot Stocks
|
Gilead announces data from OLE of two Phase 3 studies of Biktarvy »
16:18 03/07/21 03/0716:18 03/07/2116:18
GILD
Gilead
Gilead Sciences announced… Gilead Sciences announced new, long-term data from open-label extensions of two Phase 3 studies of Biktarvy, demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naive adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections. In both studies, greater than 98% of participants who initiated treatment with Biktarvy and remained in the study achieved and maintained an undetectable viral load through four years of follow-up. The high efficacy and durable viral suppression were also observed in participants who switched to Biktarvy from a dolutegravir-containing triple therapy for the 48-week OLE periods. No treatment-emergent resistance to any components of Biktarvy occurred in participants treated with Biktarvy. Gilead presented additional Biktarvy data at virtual CROI 2021, including findings from a 144-week analysis of the same Phase 3 studies, which demonstrated that people living with HIV who received initial therapy with Biktarvy reached and maintained an undetectable viral load with no treatment-emergent resistance through 144 weeks. In a subgroup analysis of participants with transmitted-drug resistance based on retrospective sequencing of baseline samples, Biktarvy achieved comparably high levels of durable viral suppression through 144 weeks among participants with and without TDR. ShowHide Related Items >><<
|
Hot Stocks
|
Atea Pharmaceuticals presents Phase 1 results for AT-527 »
16:13 03/07/21 03/0716:13 03/07/2116:13
AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals… Atea Pharmaceuticals presented results from the Phase 1 study of AT-527 in healthy volunteers at the 28th Annual Conference on Retroviruses and Opportunistic Infections in a Science Spotlight presentation. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea's purine nucleotide prodrug platform and is in Phase 2 clinical development for the treatment of COVID-19. AT-527 targets SARS-CoV-2 ribonucleic acid polymerase, a highly conserved gene which is responsible for both viral RNA replication and transcription. Given this preferential conserved target site, it is anticipated that the antiviral activity of AT-527 will continue even in the presence of naturally-evolving variants which are now emerging. In the Phase 1 study, 20 healthy volunteers were randomized 1:1 to receive oral AT-527 550 mg twice daily or matching placebo for 5 days. The purpose of this study was to assess the safety and pharmacokinetics of AT-527 in healthy volunteers and to predict human lung exposure of intracellular AT-9010, the active triphosphate metabolite of AT-527. Safety assessments included adverse events, vital signs, electrocardiograms, and standard safety laboratory tests. Intensive PK sampling, performed after the first and last two doses, provided information on plasma exposures of AT-511, the free base of AT-527, a hemisulfate salt, and its metabolites including AT-273, the guanosine nucleoside metabolite, a measurable surrogate for intracellular AT-9010. The study results showed AT-527 was well tolerated with a favorable safety profile. There were no discontinuations, serious AEs, clinically significant changes in vital signs, or ECGs observed. The data also demonstrated that AT-511 was rapidly absorbed, followed by fast and extensive stepwise metabolic activation ultimately to the intracellular TP metabolite AT-9010, reflected by plasma AT-273. AT-527 550 mg BID led to fast attainment of steady-state levels of AT-273 within two days of dosing. Plasma levels of AT-273 were further used to predict lung concentrations of AT-9010 using a scaling factor of 1.2X which was previously determined from in vivo tissue distribution of the triphosphate metabolite in cynomolgus monkeys. Beginning as early as three hours after the first dose, and maintained thereafter throughout the five days of dosing, predicted lung AT-9010 levels were consistently above the EC90 level of 0.5 microM for in vitro inhibition by the drug of SARS-CoV-2 replication. These results indicate the potential of AT-527 for the treatment of COVID-19 and are supportive of the dosing regimen of 550 mg BID. ShowHide Related Items >><<
|
Hot Stocks
|
Ridgeback, Merck announce findings from Phase 2a trial of COVID therapeutic »
16:09 03/07/21 03/0716:09 03/07/2116:09
MRK
Merck
Merck and Ridgeback… Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback's Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of molnupiravir, an investigational oral antiviral agent. The companies reported findings on one secondary objective from the Phase 2a study, showing a reduction in time to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. This multi-center U.S. Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection. The primary efficacy objective was reduction in time to viral negativity measured by reverse transcriptase polymerase chain reaction analysis of nasopharyngeal swabs. Periodic samples were collected for virologic analysis. Of the 182 participants with an evaluable nasopharyngeal swab, 42% showed detectable levels of cultured virus at baseline. Other Phase 2 and Phase 2/3 studies are underway. Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related. ShowHide Related Items >><<
|
Upgrade
|
Woolworths Group upgraded to Buy from Neutral at Goldman Sachs »
15:49 03/07/21 03/0715:49 03/07/2115:49
WOLWF
Woolworths Group
Goldman Sachs analyst… Goldman Sachs analyst Andrew McLennan upgraded Woolworths Group to Buy from Neutral with a price target of A$43.60, up from A$41.40. The analyst expects Woolworths to maintain a lead in momentum verses Coles in Supermarkets into the end of fiscal 2021 due to "superior execution in online." |
Upgrade
|
Nippon Steel upgraded to Conviction Buy from Buy at Goldman Sachs »
15:46 03/07/21 03/0715:46 03/07/2115:46
NISTF
Nippon Steel
Goldman Sachs analyst… Goldman Sachs analyst Yusuke Akiyama added Nippon Steel to the firm's Conviction List and reiterates a Buy rating on the shares with a price target of 2,150 yen, up from 2,050 yen. "Robust demand" in China will lead to a strengthening of Asian steel prices, says the analyst, who sees a "strong possibility" that the Chinese government will continue to curb steel production capacity and place more stringent restrictions on output in 2021. ShowHide Related Items >><<
|
Upgrade
|
Kobe Steel upgraded to Neutral from Sell at Goldman Sachs »
15:44 03/07/21 03/0715:44 03/07/2115:44
KBSTF
Kobe Steel
Goldman Sachs analyst… Goldman Sachs analyst Yusuke Akiyama upgraded Kobe Steel to Neutral from Sell with a price target of 600 yen, up from 510 yen. Kobe Steel's capacity utilization is improving amid a demand side boost reflecting upbeat demand in China and the recovery in end demand, Akiyama tells investors in a research note. ShowHide Related Items >><<
|
Upgrade
|
Larsen & Toubro upgraded to Conviction Buy from Buy at Goldman Sachs »
15:41 03/07/21 03/0715:41 03/07/2115:41
LTOUF
Larsen & Toubro
Goldman Sachs analyst… Goldman Sachs analyst Pulkit Patni added Larsen & Toubro to the firm's Conviction List and reiterates a Buy rating on the shares with a price target of INR 2,055, up from INR 1,650. The Union budget increased confidence on the continuity of government spending, which, along with rising capacity utilization for the manufacturing industry and the "Make in India" initiative bode well for Larsen & Toubro, Patni tells investors in a research note. ShowHide Related Items >><<
|
On The Fly
|
Opening Day: InnovAge rises, Oscar Health slips on first trading day »
09:14 03/07/21 03/0709:14 03/07/2109:14
INNV
InnovAge
Oscar Health
VPC Impact Acquisition Holdings III
VPC Impact Acquisition Holdings II
Warburg Pincus Capital Corporation I-A
Tribe Capital Growth Corp I
Warburg Pincus Capital Corporation I-B
dMY Technology Group IV
Tailwind Two Acquisition
First Reserve Sustainable Growth
InterPrivate IV InfraTech Partners
InterPrivate III Financial Partners
InterPrivate II Acquisition
Property Solutions Acquisition II
Khosla Ventures Acquisition
Aurora Acquisition
Altimar Acquisition Corp. III
Twin Ridge Capital Acquisition
Isos Acquisition
Mission Advancement
Roth CH Acquisition III
DHB Capital
Goldenbridge Acquisition
TCW Special Purpose Acquisition
FinTech Evolution Acquisition
Supernova Partners Acquisition II
Orion Acquisition
NightDragon Acquisition
Anzu Special Acquisition Corp I
Northern Star Investment Corp. IV
Northern Star Investment Corp. III
Live Oak Mobility Acquisition
Advanced Merger Partners
Coinbase
Roblox
Vizio
Gold Royalty
Alignment Healthcare
Robinhood
Palantir
Asana
Slack Technologies
Spotify
Alibaba
Elder-care company… ShowHide Related Items >><<
|
Conference/Events
|
Super Micro Computer participates in a conference call with Northland »
16:53 03/06/21 03/0616:53 03/06/2116:53
SMCI
Super Micro Computer
Conference call with CFO… Conference call with CFO Weigand will be held on March 12 at 12 pm. Webcast Link ShowHide Related Items >><<
|
Conference/Events
|
Accuray participates in a conference call with Northland »
16:51 03/06/21 03/0616:51 03/06/2116:51
ARAY
Accuray
Cconference call with… Cconference call with President & CEO Levine and CCO Winter will be held on March 15 at 12 pm. Webcast Link ShowHide Related Items >><<
|
Periodicals
|
Cisco, Qualcomm offer solid yield, dividend growth, Barron's says »
12:36 03/06/21 03/0612:36 03/06/2112:36
AVGO
Broadcom
Cisco
Qualcomm
Texas Instruments
It's hard to find… It's hard to find attractive yields with dividend growth among tech stock but Broadcom (AVGO), Cisco (CSCO), Qualcomm (QCOM) and Texas Instruments (TXN) offer both, Lawrence Strauss writes on this week's edition of Barron's. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Vertex underperformance after drug setback a buying opportunity, Barron's says »
12:19 03/06/21 03/0612:19 03/06/2112:19
VRTX
Vertex Pharmaceuticals
For nearly a decade,… For nearly a decade, Vertex Pharmaceuticals could do no wrong but then the biotech company canceled development of a once-promising drug after trial results disappointed and its stock is now down 25% since mid-October, Josh Nathan-Kazis writes in this week's edition of Barron's. The pullback has been overdone, the author contends, adding that there is an opportunity now for investors to get back in. Reference Link ShowHide Related Items >><<
|